Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Newer

InkynClyde

05/21/21 1:47 PM

Post #10

Tally Ho!

stockguard

04/08/21 11:23 AM

Post #9

04/08/2021
Hookipa Pharma initiated with an Overweight at Morgan Stanley Morgan Stanley analyst Vikram Purohit initiated coverage of Hookipa Pharma with an Overweight rating and $19 price target. Hookipa is developing candidates for cancer and infectious disease using its arenavirus platform and its initial clinical data for HB-201 in HPV16+ cancer provides early proof-of-concept, Purohit tells investors. The analyst estimates peak product sales of HB-201 in HPV16+ head and neck cancer of about $400M in 2030, assuming a launch in 2024 and assigning the program 75% odds of success. Overweight and $19 PT.

stockguard

02/18/21 4:15 PM

Post #8

Getting some love of late:
HOOKIPA PHARMA (NASDAQ HOOK) INSTITUTIONAL BUYING AND SELLING
https://www.marketbeat.com/stocks/NASDAQ/HOOK/institutional-ownership/

stockguard

01/01/21 11:40 AM

Post #7

Hookipa: Data Readouts Of 2021's HB-101, HB-201, And HB-201/-202 Hold Promising Upside
https://seekingalpha.com/article/4396866-hookipa-data-readouts-of-2021s-hbminus-101-hbminus-201-and-hbminus-201minus-202-hold

stockguard

11/30/20 2:22 PM

Post #6

11/30/2020
Hookipa Pharma price target raised to $25 from $19 at JMP Securities
HOOK JMP Securities analyst Roy Buchanan raised the firm's price target on Hookipa Pharma to $25 from $19 and keeps an Outperform rating on the shares after the company announced interim results from the Phase 2 trial of HB-101 to vaccinate CMV- transplant patients receiving a CMV+ kidney. The analyst believes that good immune and viremia results for the three-dose group indicate that HB-101 can produce clinical benefit for this important and difficult indication, and provide additional validation of the platform.

stockguard

11/03/20 11:24 AM

Post #5

Hookipa Pharma initiated with a Buy at Truist
Truist analyst Asthika Goonewardene initiated coverage of Hookipa Pharma with a Buy rating and $21 price target. The analyst is positive on the company's efforts in building an immuno-oncology and infectious disease pipeline around its proprietary viral vector platform, which he finds "compelling" given the "profound" immune priming effect that it has demonstrated to date.